ArticleRetrovirology2007
Trans-inhibition of HIV-1 by a long hairpin RNA expressed within the viral genome.
Article in Retrovirology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 25 citations in OpenAlex.
- Genetic recombination in plant-infecting messenger-sense RNA viruses: overview and research perspectives.Frontiers in plant science · 2013Article
- Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100.BMC biotechnology · 2012Article
- HIVsirDB: a database of HIV inhibiting siRNAs.PloS one · 2011Article
- A direct comparison of strategies for combinatorial RNA interference.BMC molecular biology · 2010Article
- Toward a durable anti-HIV gene therapy based on RNA interference.Annals of the New York Academy of Sciences · 2009Review
- Lentiviral delivery of short hairpin RNAs.Advanced drug delivery reviews · 2009Review
- Oncoviruses and Pathogenic MicroRNAs in Humans.The open virology journal · 2009Article
- Nucleic acids-based therapeutics in the battle against pathogenic viruses.Handbook of experimental pharmacology · 2009Review
- Progress in the therapeutic applications of siRNAs against HIV-1.Methods in molecular biology (Clifton, N.J.) · 2009Review
- The 2008 Retrovirology Prize: Ben Berkhout and his RNA world.Retrovirology · 2008Article
- Progress and prospects: RNA-based therapies for treatment of HIV infection.Gene therapy · 2007Review
- The silent defense: micro-RNA directed defense against HIV-1 replication.Retrovirology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHuman immunodeficiency virus type 1 (HIV-1) can be inhibited by means of RNA silencing or interference (RNAi) using synthetic short interfering RNAs (siRNAs) or gene constructs encoding short hairpin RNAs (shRNAs) or long hairpin RNAs (lhRNAs). The use of siRNA and shRNA as antiviral therapeutic is limited because of the emergence of viral escape mutants. This problem is theoretically prevented by intracellular expression of lhRNAs generating multiple siRNAs that target the virus simultaneously, thus reducing the chance of viral escape. However, gene constructs encoding lhRNA molecules face problems with delivery to the right cells in an infected individual. In order to solve this problem, we constructed an HIV-1 variant with a 300 bp long hairpin structure in the 3' part of the genome corresponding to the Nef gene (HIV-lhNef).
resultsIntriguingly, HIV-lhNef potently inhibited wild-type HIV-1 production in trans. However, HIV-lhNef demonstrated a severe production and replication defect, which we were able to solve by selecting spontaneous virus variants with truncated hairpin structures. Although these escape variants lost the ability to trans-inhibit HIV-1, they effectively outgrew the wild-type virus in competition experiments in SupT1 cells.
conclusionExpression of the lhNef hairpin within the HIV-1 genome results in potent trans-inhibition of wild-type HIV-1. Although the mechanism of trans-inhibition is currently unknown, it remains of interest to study the molecular details because the observed effect is extremely potent. This may have implications for the development of virus strains to be used as live-attenuated virus vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.